Prostate Cancer Screening and Treatment in the Transplant Population: Current Status and Recommendations

Benjamin N. Breyer, Jared M Whitson, Christopher E. Freise, Maxwell V. Meng

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Purpose: We reviewed the current status of and recommendations for prostate cancer screening and treatment in the solid organ transplant population. Materials and Methods: We performed a MEDLINE® search to identify published data regarding prostate cancer screening, risk, treatment and outcomes in the solid organ transplant population. The literature was reviewed and summarized. Results: Most data regarding outcomes of prostate cancer treatment in the transplant population are limited to case reports and small series, and primarily involve renal insufficiency. It does not appear that the development or natural history of prostate cancer is significantly affected by organ failure or subsequent transplantation. Thus, prostate specific antigen testing and screening protocols can be extrapolated from the general population. However, the balance of comorbid diseases and estimated limitations in life expectancy must be carefully considered, and emphasis should be placed on risk assessment. Prostatectomy appears to be feasible with outcomes comparable to those in the non-transplant population, while data regarding the use of radiation therapy are limited. Conclusions: The expansion of organ transplant criteria, including older donors and recipients, combined with improved allograft survival has enhanced the relevance of prostate cancer screening and treatment in this group. Greater awareness of the issues surrounding prostate cancer incidence, detection and natural history should promote improved data collection, screening and treatment of prostate cancer in the transplant population.

Original languageEnglish (US)
Pages (from-to)2018-2026
Number of pages9
JournalJournal of Urology
Volume181
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Transplants
Population
Therapeutics
Prostate-Specific Antigen
Prostatectomy
Life Expectancy
Natural History
MEDLINE
Renal Insufficiency
Allografts
Radiotherapy
Transplantation
Incidence

Keywords

  • graft survival
  • prostate-specific antigen
  • prostatic neoplasms
  • transplantation

ASJC Scopus subject areas

  • Urology

Cite this

Prostate Cancer Screening and Treatment in the Transplant Population : Current Status and Recommendations. / Breyer, Benjamin N.; Whitson, Jared M; Freise, Christopher E.; Meng, Maxwell V.

In: Journal of Urology, Vol. 181, No. 5, 05.2009, p. 2018-2026.

Research output: Contribution to journalReview article

Breyer, Benjamin N. ; Whitson, Jared M ; Freise, Christopher E. ; Meng, Maxwell V. / Prostate Cancer Screening and Treatment in the Transplant Population : Current Status and Recommendations. In: Journal of Urology. 2009 ; Vol. 181, No. 5. pp. 2018-2026.
@article{b9ef62f199214d07856cd5e129b3e09a,
title = "Prostate Cancer Screening and Treatment in the Transplant Population: Current Status and Recommendations",
abstract = "Purpose: We reviewed the current status of and recommendations for prostate cancer screening and treatment in the solid organ transplant population. Materials and Methods: We performed a MEDLINE{\circledR} search to identify published data regarding prostate cancer screening, risk, treatment and outcomes in the solid organ transplant population. The literature was reviewed and summarized. Results: Most data regarding outcomes of prostate cancer treatment in the transplant population are limited to case reports and small series, and primarily involve renal insufficiency. It does not appear that the development or natural history of prostate cancer is significantly affected by organ failure or subsequent transplantation. Thus, prostate specific antigen testing and screening protocols can be extrapolated from the general population. However, the balance of comorbid diseases and estimated limitations in life expectancy must be carefully considered, and emphasis should be placed on risk assessment. Prostatectomy appears to be feasible with outcomes comparable to those in the non-transplant population, while data regarding the use of radiation therapy are limited. Conclusions: The expansion of organ transplant criteria, including older donors and recipients, combined with improved allograft survival has enhanced the relevance of prostate cancer screening and treatment in this group. Greater awareness of the issues surrounding prostate cancer incidence, detection and natural history should promote improved data collection, screening and treatment of prostate cancer in the transplant population.",
keywords = "graft survival, prostate-specific antigen, prostatic neoplasms, transplantation",
author = "Breyer, {Benjamin N.} and Whitson, {Jared M} and Freise, {Christopher E.} and Meng, {Maxwell V.}",
year = "2009",
month = "5",
doi = "10.1016/j.juro.2009.01.021",
language = "English (US)",
volume = "181",
pages = "2018--2026",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prostate Cancer Screening and Treatment in the Transplant Population

T2 - Current Status and Recommendations

AU - Breyer, Benjamin N.

AU - Whitson, Jared M

AU - Freise, Christopher E.

AU - Meng, Maxwell V.

PY - 2009/5

Y1 - 2009/5

N2 - Purpose: We reviewed the current status of and recommendations for prostate cancer screening and treatment in the solid organ transplant population. Materials and Methods: We performed a MEDLINE® search to identify published data regarding prostate cancer screening, risk, treatment and outcomes in the solid organ transplant population. The literature was reviewed and summarized. Results: Most data regarding outcomes of prostate cancer treatment in the transplant population are limited to case reports and small series, and primarily involve renal insufficiency. It does not appear that the development or natural history of prostate cancer is significantly affected by organ failure or subsequent transplantation. Thus, prostate specific antigen testing and screening protocols can be extrapolated from the general population. However, the balance of comorbid diseases and estimated limitations in life expectancy must be carefully considered, and emphasis should be placed on risk assessment. Prostatectomy appears to be feasible with outcomes comparable to those in the non-transplant population, while data regarding the use of radiation therapy are limited. Conclusions: The expansion of organ transplant criteria, including older donors and recipients, combined with improved allograft survival has enhanced the relevance of prostate cancer screening and treatment in this group. Greater awareness of the issues surrounding prostate cancer incidence, detection and natural history should promote improved data collection, screening and treatment of prostate cancer in the transplant population.

AB - Purpose: We reviewed the current status of and recommendations for prostate cancer screening and treatment in the solid organ transplant population. Materials and Methods: We performed a MEDLINE® search to identify published data regarding prostate cancer screening, risk, treatment and outcomes in the solid organ transplant population. The literature was reviewed and summarized. Results: Most data regarding outcomes of prostate cancer treatment in the transplant population are limited to case reports and small series, and primarily involve renal insufficiency. It does not appear that the development or natural history of prostate cancer is significantly affected by organ failure or subsequent transplantation. Thus, prostate specific antigen testing and screening protocols can be extrapolated from the general population. However, the balance of comorbid diseases and estimated limitations in life expectancy must be carefully considered, and emphasis should be placed on risk assessment. Prostatectomy appears to be feasible with outcomes comparable to those in the non-transplant population, while data regarding the use of radiation therapy are limited. Conclusions: The expansion of organ transplant criteria, including older donors and recipients, combined with improved allograft survival has enhanced the relevance of prostate cancer screening and treatment in this group. Greater awareness of the issues surrounding prostate cancer incidence, detection and natural history should promote improved data collection, screening and treatment of prostate cancer in the transplant population.

KW - graft survival

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=64049084828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049084828&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.01.021

DO - 10.1016/j.juro.2009.01.021

M3 - Review article

C2 - 19286214

AN - SCOPUS:64049084828

VL - 181

SP - 2018

EP - 2026

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -